adalimumab vs JNJ-78934804
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00055497 · Phase 3 · completed
Design meets top-tier criteria (randomized, quadruple-blind, placebo-controlled, hard clinical endpoint), but the randomized comparison population was very small (only 55 total randomized participants across 3 arms) and the two primary analysis methods gave discordant significance results (NRI missed, LOCF met), which per the definitions caps this at moderate under both the underpowered-n and mixed/unclear-primary-result tests.
Next expected readout: June 2027 · NCT06045754 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) (met)
Result source: NCT02499783
JNJ-78934804
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07577843 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | JNJ-78934804 |
|---|---|---|
| Clinical remission (induction) | 37.3% vs 6.8%+30.5 vs placeboNCT024997831 other result
| —Trial running · NCT07577843 |
| Endoscopic response (induction) | —Trial running · NCT05040464 | —Trial running · NCT07577843 |
| Clinical remission (maintenance) | 47.4% vs 33.3%+14.1 vs placeboNCT0005549711 other results
| —Trial running · NCT07577843 |
| Endoscopic response (maintenance) | —Trial running · NCT05040464 | —Trial running · NCT07577843 |
Clinical remission (induction)
- adalimumab
- 37.3% vs 6.8%+30.5 vs placeboNCT02499783
1 other result
- 46.9% vs 27.7% NCT00348283
- JNJ-78934804
- —Trial running · NCT07577843
Endoscopic response (induction)
- adalimumab
- —Trial running · NCT05040464
- JNJ-78934804
- —Trial running · NCT07577843
Clinical remission (maintenance)
- adalimumab
- 47.4% vs 33.3%+14.1 vs placeboNCT00055497
11 other results
- 66.7% vs 33.3% NCT00055497
- 78.9% vs 44.4% NCT00055497
- 83.3% vs 44.4% NCT00055497
- 38.1% vs 9.1% NCT00445432
- 36.3% vs 38.9% NCT00055497
- 40.2% vs 38.9% NCT00055497
- 32.8% vs 9.2% NCT00348283
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- JNJ-78934804
- —Trial running · NCT07577843
Endoscopic response (maintenance)
- adalimumab
- —Trial running · NCT05040464
- JNJ-78934804
- —Trial running · NCT07577843
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
JNJ-78934804: no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab: 4 of 4 rows · JNJ-78934804: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab |
|---|---|
| Dropout rate | —40 mg every other weeka NCT00055497 · Phase 3 show 34 more results15.8%40 mg every other week NCT00055497 · Phase 3 11.1%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 40.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 48.5% NCT00195715 · Phase 3 16.9%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.4% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 6.8%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 6.8%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 21.4% NCT02185014 · Phase 3 · monotherapy 61% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 60%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 34.4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 35.7%80 mg NCT01958827 · Phase 3 · monotherapy 16.4%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 36% NCT02148718 · Phase 4 · registry result, not featured evidence 26.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 26.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —40 mg every other weeka NCT00055497 · Phase 3 show 34 more results5.3%40 mg every other week NCT00055497 · Phase 3 5.6%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 12.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 15.7% NCT00195715 · Phase 3 6%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 1.5% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 3.9%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 2.4%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 7.1% NCT02185014 · Phase 3 · monotherapy 8% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 21.9%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 10.7%80 mg NCT01958827 · Phase 3 · monotherapy 10.9%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination — NCT02148718 · Phase 4 · registry result, not featured evidence 20%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 20%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.3%40 mg every other weeka NCT00055497 · Phase 3 show 34 more results—40 mg every other week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 0%40 mg every week NCT00055497 · Phase 3 16.7%40 mg NCT00055497 · Phase 3 2%160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 38.1% NCT00195715 · Phase 3 —40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 14.8% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.5%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 4.9%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy 4.6%Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy 6.4%Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 10.7% NCT02185014 · Phase 3 · monotherapy 48% NCT00686374 · Phase 3 · monotherapy 23.7%40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20%20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 8%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 40.6%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 28.6%80 mg NCT01958827 · Phase 3 · monotherapy —40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 2.3% NCT02148718 · Phase 4 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 7.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 14.3%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 40 mg every other weeka nasopharyngitis 26.3% (placebo 38.9%) crohn's disease aggravated 21.1% (placebo 27.8%) sinusitis 21.1% (placebo 5.6%) NCT00055497 · Phase 3 show 28 more results40 mg every week crohn's disease aggravated 11.1% (placebo 27.8%) dizziness (excl vertigo) 11.1% (placebo 5.6%) nasopharyngitis 11.1% (placebo 38.9%) NCT00055497 · Phase 3 40 mg crohn's disease aggravated 17.6% (placebo 27.8%) nasopharyngitis 16.7% (placebo 38.9%) headache 14% (placebo 11.1%) NCT00055497 · Phase 3 160/80 mg white blood cell count decreased 5.9% (placebo 1%) cough 4.9% (placebo 0%) dizziness 3.9% (placebo 0%) NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg every other week or every week headache 18.9% nasopharyngitis 14.4% arthralgia 7.6% NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 crohn's disease 23.4% (placebo 29.2%) headache 14.1% (placebo 9.2%) nasopharyngitis 14.1% (placebo 12.3%) NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 viral upper respiratory tract infection 39% headache 37% upper respiratory tract infection 31% NCT00686374 · Phase 3 · monotherapy 40 mg or 20 mg every other week headache 17.2% crohn's disease 11.8% nausea 10.8% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20 mg or 10 mg every other week headache 21.1% crohn's disease 15.8% nasopharyngitis 11.6% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg Eow nasopharyngitis 56% (placebo 12%) rhinorrhoea 16% (placebo 0%) adverse drug reaction 12% (placebo 4%) NCT00445432 · Phase 2/3 · monotherapy 40 mg Eow nasopharyngitis 71.9% (placebo 12%) adverse drug reaction 18.8% (placebo 4%) iron deficiency anaemia 18.8% (placebo 0%) NCT00445432 · Phase 2/3 · monotherapy 160 mg/80 mg + 40/40 mg adverse drug reaction 11.1% (placebo 4.3%) application site swelling 11.1% (placebo 0%) blood creatine phosphokinase (at investigator's discretion) 11.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 160 mg/80 mg headache 9.1% (placebo 4.3%) upper respiratory tract infection 9.1% (placebo 4.3%) abdominal distension 6.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80/40 mg + 40/40 mg headache 16.7% (placebo 4.3%) abdominal distension 8.3% (placebo 0%) abdominal pain 8.3% (placebo 4.3%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80 mg/40 mg injection site reaction 8.8% (placebo 8.7%) malaise 8.8% (placebo 0%) rhinorrhoea 8.8% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 40 mg every other week crohn's disease 16.1% abdominal pain 7.6% injection site reaction 7.6% NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) arthralgia 18.2% crohn's disease 16.4% nasopharyngitis 10.9% NCT02764762 · Phase 4 · registry result, not featured evidence · combination vomiting 7% abdominal mass 5.8% arthralgia 4.7% NCT02148718 · Phase 4 · registry result, not featured evidence Low Induction Dose leukopenia 20% pyrexia 13.3% arthralgia 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Low Induction Dose leukopenia 15.4% animal bite 7.7% aphthous stomatitis 7.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose alanine aminotransferase increased 13.3% aspartate aminotransferase increased 13.3% abdominal pain 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose mycobacterium tuberculosis complex test positive 14.3% aspartate aminotransferase increased 7.1% asthenia 7.1% NCT02015793 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 11 more results
show 80 more results
show 11 more results
show 11 more results
show 6 more results
show 1 more result
show 4 more results
+ 62 further endpoints in the CSV export.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00385736 · Phase 3 · completed
Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.
Next expected readout: September 2027 · NCT06257875 (registry estimate)
Reported efficacy
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)
Result source: NCT00408629
JNJ-78934804
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2028 · NCT07577856 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | JNJ-78934804 |
|---|---|---|
| Clinical remission (induction) | 10% vs 11.5%−1.5 vs placeboNCT008530996 other results
| —Trial running · NCT07577856 |
| Clinical remission (maintenance) | 20% vs 7.3%+12.7 vs placeboNCT0085309914 other results
| —Trial running · NCT07577856 |
| Clinical response (induction) | 50% vs 35.4%+14.6 vs placeboNCT008530994 other results
| —Trial running · NCT07577856 |
| Endoscopic improvement (induction) | 44.4% vs 30.2%+14.2 vs placeboNCT008530992 other results
| —Trial running · NCT07577856 |
| Corticosteroid-free remission (maintenance) | 13.3% vs 5.7%+7.6 vs placeboNCT004086295 other results
| —Trial running · NCT07577856 |
Clinical remission (induction)
- adalimumab
- 10% vs 11.5%−1.5 vs placeboNCT00853099
6 other results
- 13.8% vs 11.5% NCT00853099
- 10% vs 9.2% NCT00385736
- 18.5% vs 9.2% NCT00385736
- 16.5% vs 9.3% NCT00408629
- 10% vs 11.5% NCT00853099
- 13.8% vs 11.5% NCT00853099
- JNJ-78934804
- —Trial running · NCT07577856
Clinical remission (maintenance)
- adalimumab
- 20% vs 7.3%+12.7 vs placeboNCT00853099
14 other results
- 26.4% vs 7.3% NCT00853099
- 17.3% vs 8.5% NCT00408629
- 29% vs 33.3% NCT02065557
- 45.2% vs 33.3% NCT02065557
- 27.3% vs 33.3% NCT02065557
- 42.9% vs 33.3% NCT02065557
- 20% vs 7.3% NCT00853099
- 17.8% vs 8.3% NCT00853099
- 26.4% vs 7.3% NCT00853099
- 17.2% vs 8.3% NCT00853099
- 42.9% vs 37.5% NCT02065557
- 45.5% vs 37.5% NCT02065557
- 42.9% vs 37.5% NCT02065557
- 44% vs 37.5% NCT02065557
- JNJ-78934804
- —Trial running · NCT07577856
Clinical response (induction)
- adalimumab
- 50% vs 35.4%+14.6 vs placeboNCT00853099
4 other results
- 42.5% vs 35.4% NCT00853099
- 54.6% vs 44.6% NCT00385736
- 51.5% vs 44.6% NCT00385736
- 50.4% vs 34.6% NCT00408629
- JNJ-78934804
- —Trial running · NCT07577856
Endoscopic improvement (induction)
- adalimumab
- 44.4% vs 30.2%+14.2 vs placeboNCT00853099
2 other results
- 39.1% vs 30.2% NCT00853099
- 41.1% vs 31.7% NCT00408629
- JNJ-78934804
- —Trial running · NCT07577856
Corticosteroid-free remission (maintenance)
- adalimumab
- 13.3% vs 5.7%+7.6 vs placeboNCT00408629
5 other results
- 13.3% vs 5.7% NCT00408629
- 30.8% vs 40% NCT02065557
- 31.3% vs 40% NCT02065557
- 26.7% vs 40% NCT02065557
- 35.3% vs 40% NCT02065557
- JNJ-78934804
- —Trial running · NCT07577856
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
JNJ-78934804: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab: 4 of 4 rows · JNJ-78934804: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab |
|---|---|
| Dropout rate | 6.9%160/80/40a NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results9.2%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 37.6%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 52.5% NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 10.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 56.4%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 34.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 33.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 23.8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Discontinued due to AEs | 3.1%160/80/40a NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results4.6%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 — NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 13.8%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 14.3%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 10.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5.6% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Serious AEs | 4%160/80/40a NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results3.8%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 12.1%Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 27.1% NCT02632175 · Phase 3 · monotherapy 7.8%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 5.6%open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.6%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 13.9%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.2%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.8%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 5%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.6%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.8%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 9.9%Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 26.7%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 11.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 16.1%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.5% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Most frequent reported AEs | 160/80/40a colitis ulcerative 4% (placebo 3.6%) fatigue 4% (placebo 2.2%) headache 3.1% (placebo 7.2%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 17 more results80/40 headache 6.9% (placebo 7.2%) colitis ulcerative 5.4% (placebo 3.6%) nasopharyngitis 4.6% (placebo 1.8%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 nasopharyngitis 17.5% (placebo 10.4%) colitis ulcerative 16.3% (placebo 22.3%) headache 8.6% (placebo 14.2%) NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 33.9% upper respiratory tract infection 27.1% nasopharyngitis 22% NCT02632175 · Phase 3 · monotherapy high dose headache 9.8% (placebo 16.7%) anaemia 5.9% (placebo 8.3%) nausea 5.9% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 open-label high dose headache 22.2% (placebo 16.7%) abdominal pain 11.1% (placebo 8.3%) oropharyngeal pain 11.1% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 12.5% (placebo 16.7%) colitis ulcerative 6.3% (placebo 16.7%) nasopharyngitis 6.3% (placebo 8.3%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 high dose colitis ulcerative 11.1% (placebo 16.7%) nasopharyngitis 11.1% (placebo 8.3%) upper respiratory tract infection 11.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 18.2% (placebo 16.7%) c-reactive protein increased 9.1% (placebo 0%) colitis ulcerative 9.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 8.4% nasopharyngitis 5.1% arthralgia 3.1% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 6.1% colitis ulcerative 5.3% nasopharyngitis 4.2% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 13.4% nasopharyngitis 13.1% arthralgia 6.6% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 17.4% nasopharyngitis 13.6% arthralgia 6.7% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 15.2% nasopharyngitis 7.3% upper respiratory tract infection 6% NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 40 mg EOW/EW colitis ulcerative 30.4% viral upper respiratory tract infection 19.4% arthralgia 10.5% NCT00573794 · Phase 3 · monotherapy 160 mg/80 mg nasopharyngitis 33.3% (placebo 21.9%) iron deficiency anaemia 8.9% (placebo 7.3%) headache 7.8% (placebo 6.3%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 80 mg/40 mg nasopharyngitis 21.8% (placebo 21.9%) injection site reaction 8% (placebo 2.1%) dental caries 6.9% (placebo 5.2%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 13.2% headache 13% nasopharyngitis 8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 6 more results
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 14 more results
show 8 more results
show 2 more results
+ 51 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · JNJ-78934804's landscape